What's new — Colorectal adenocarcinoma¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 0 |
| last 3 months | 3 |
| last 6 months | 4 |
| last year | 8 |
| older than a year | 284 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-07-02 | Disparities in colonoscopy adherence and neoplasia detection after positive fecal immunochemical test: a retrospective matched cohort study — Cancer Causes Control ([PMID 42517977](https://pubmed.ncbi.nlm.nih.gov/42517977/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-07-02 | Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias — EBioMedicine ([PMID 42508231](https://pubmed.ncbi.nlm.nih.gov/42508231/){target="_blank" rel="noopener"}) | biomarkers-and-liquid-biopsy |
| 2026-07-01 | Thermal ablation versus liver resection for small colorectal liver metastases (≤ 3 cm): a systematic review and meta-analysis of randomized and propensity score-matched studies — Surg Endosc ([PMID 42463528](https://pubmed.ncbi.nlm.nih.gov/42463528/){target="_blank" rel="noopener"}) | liver-and-lung-metastasis |
| 2026-05-05 | Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial — Lancet ([PMID 42102826](https://pubmed.ncbi.nlm.nih.gov/42102826/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-01-02 | Circulating Tumor DNA as a Biomarker for Recurrence After Curative Resection of Colorectal Cancer Liver Metastases: A Systematic Review and Meta-Analysis — Clin Colorectal Cancer ([PMID 41723037](https://pubmed.ncbi.nlm.nih.gov/41723037/){target="_blank" rel="noopener"}) | biomarkers-and-liquid-biopsy |
| 2026-01-02 | Psychosocial effects and quality of life after stoma surgery: systematic review and qualitative meta-synthesis — BMC Psychol ([PMID 41578363](https://pubmed.ncbi.nlm.nih.gov/41578363/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-11-01 | Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis — Eur J Cancer ([PMID 41197289](https://pubmed.ncbi.nlm.nih.gov/41197289/){target="_blank" rel="noopener"}) | liver-and-lung-metastasis |
| 2025-10-02 | Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial — Nat Med ([PMID 41115959](https://pubmed.ncbi.nlm.nih.gov/41115959/){target="_blank" rel="noopener"}) | biomarkers-and-liquid-biopsy, clinical-trials-landscape, localized-colon-cancer |
Trials — what has moved¶
31 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 6 |
| trial records updated in the last 2 months | 10 |
| trial records updated in the last 3 months | 12 |
| trial records updated in the last 6 months | 17 |
| trial records updated in the last year | 22 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-07-22 | Sotorasib and Panitumumab Versus Investigator's Choice for Participant | PHASE3 | 160 | Progression-free Survival (PFS) Per Response Evaluation Criteria in So | 46 | 152 | 56 |
| 2026-06-11 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in | PHASE3 | 841 | SLI: Number of Participants With Dose Limiting Toxicity (DLTs) | 321 | 790 | 400 |
| 2025-09-22 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Cho | PHASE3 | 839 | Progression-free Survival (PFS) by Blinded Independent Review Center ( | 431 | 807 | 339 |
| 2023-04-18 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | PHASE2 | 117 | Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded I | 29 | 133 | 71 |
26 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| biomarkers-and-liquid-biopsy | 2026-07-02 | 3 | 25 |
| screening-and-early-detection | 2026-07-02 | 2 | 26 |
| liver-and-lung-metastasis | 2026-07-01 | 2 | 26 |
| patient-experience-and-advocacy | 2026-01-02 | 1 | 26 |
| clinical-trials-landscape | 2025-10-02 | 1 | 19 |
| localized-colon-cancer | 2025-10-02 | 1 | 25 |
| hereditary-syndromes-and-genetics | 2025-07-03 | 0 | 26 |
| epidemiology-and-burden | 2025-04-02 | 0 | 25 |
| localized-rectal-cancer | 2025-04-02 | 0 | 25 |
| survivorship-and-late-effects | 2025-04-02 | 0 | 26 |
| guidelines | 2025-01-02 | 0 | 34 |
| metastatic-systemic-therapy | 2025-01-02 | 0 | 25 |
| overview | 2025-01-02 | 0 | 49 |
| precision-oncology | 2025-01-02 | 0 | 25 |
| red-flags-and-safety-concerns | 2025-01-02 | 0 | 25 |
| molecular-subtypes-and-tumor-microenvironment | 2024-09-04 | 0 | 26 |
| pathology-staging-and-diagnostic-workup | 2024-09-01 | 0 | 25 |
| adenoma-carcinoma-and-serrated-pathways | 2024-03-07 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.